# AI in Drug Discovery: AlphaFold, RoseTTAFold, and Generative Molecular Design

## Description

AI is revolutionizing drug discovery, primarily through protein structure prediction (AlphaFold, RoseTTAFold) and Generative Molecular Design (GMD). AlphaFold3, in particular, expanded structure prediction to entire biomolecular complexes (proteins, nucleic acids, ligands), providing a holistic view for drug design. GMD, using AI models such as Transformers and Diffusion Models, enables the *de novo* creation of molecules with optimized properties (efficacy, ADMET), accelerating the R&D pipeline and drastically reducing development time and cost.

## Statistics

**Reduction in Discovery Time:** From 10-15 years to 1-2 years (a reduction of up to 70%). **Phase I Success Rate:** 80-90% for AI-discovered molecules (vs. the historical industry average). **Cost Reduction:** Projected 15% to 22% cost reduction across all phases over the next 3-5 years. **Interaction Accuracy (AlphaFold3):** 50% improvement in modeling biomolecular interactions. **Confidence Metric:** AlphaFold uses pLDDT (predicted Local Distance Difference Test) for per-residue accuracy.

## Features

Protein Structure Prediction (AlphaFold/RoseTTAFold); Biomolecular Complex Prediction (AlphaFold3); Generative Molecular Design (*de novo* design); ADMET/Tox Property Optimization; Virtual Screening at Scale (Geometric Deep Learning).

## Use Cases

**Drug Repurposing:** Identifying new uses for existing drugs (e.g., baricitinib for COVID-19). **Protein Inhibitor Design:** Using AlphaFold-predicted structures to design small-molecule inhibitors. **Molecules in Clinical Trials:** Several AI-designed molecules have already entered clinical trials. **Synthetic Protein Design:** Using RoseTTAFold and related tools (RFDesign) to design proteins with novel functions. **Virtual Screening at Scale:** Using geometric Deep Learning models to explore ultra-large chemical libraries.

## Integration

Integration is primarily carried out through open-source libraries such as **DeepChem** (for molecular property and toxicity modeling) and open-source implementations of models such as **RoseTTAFold** (available on GitHub for local installation and execution). Commercial platforms such as Iktos AI and NVIDIA BioNeMo offer APIs and integrated environments.
\n\n**Integration Example (DeepChem for Property Prediction):**
\n```python
\nimport deepchem as dc
\n\n# 1. Load a toxicity dataset (example: Tox21)
\ntasks, datasets, transformers = dc.molnet.load_tox21(featurizer='GraphConv')
\ntrain_dataset, valid_dataset, test_dataset = datasets
\n\n# 2. Build and train a GCN model
\nmodel = dc.models.GraphConvModel(len(tasks), batch_size=50)
\nmodel.fit(train_dataset, nb_epoch=10)
\n\n# 3. Predict toxicity for a new molecule (SMILES)
\nsmiles = ['CC(=O)Oc1ccccc1C(=O)O'] # Aspirin
\nfeaturizer = dc.feat.GraphConvFeaturizer()
\nnew_mol_dataset = dc.data.NumpyDataset(X=featurizer.featurize(smiles))
\nprediction = model.predict(new_mol_dataset)
\nprint(f"Toxicity Prediction (Aspirin): {prediction}")
\n```
\n\n**Integration Example (RoseTTAFold via GitHub):**
\n```bash
\n# Clone the official RoseTTAFold repository
\ngit clone https://github.com/RosettaCommons/RoseTTAFold
\n# Install dependencies and run the prediction (conceptual process)
\npython run_RoseTTAFold.py --input_fasta my_protein.fasta --output_dir results/
\n```

## URL

AlphaFold: https://deepmind.google/science/alphafold/ | RoseTTAFold (GitHub): https://github.com/RosettaCommons/RoseTTAFold | DeepChem: https://deepchem.io/
